LEGIONELLA IN THE VIEW OF SPECIALISTS - page 73

71
References
Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care--associated pneumonia,
2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.
MMWR Recomm Rep. Mar 26 2004;53(RR-3):1-36.
Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, et al. Antimicrobial chemotherapy for
Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. Mar 15 2005;40(6):800-6
Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire’s disease.
The Ohio Community-Based Pneumonia Incidence Study Group. Chest. Feb 2000;117(2):398-403.
Sopena N, Sabria-Leal M, Pedro-Botet ML, et al. Comparative study of the clinical presentation of
Legionella pneumonia and other community-acquired pneumonias. Chest. May 1998;113(5):1195-200.
Plouffe JF, File TM Jr, Breiman RF, et al. Reevaluation of the definition of Legionnaires’ disea- se: use of the
urinary antigen assay. Clin Infect Dis 1995;20:1286-1291
Pedro-Botet ML, et al. Epidemiology and pathogenesis of Legionella infection.http://www.uptodate.com/
home. Accessed June 26, 2013.
Legionella (Legionnaires’ disease and Pontiac fever). Centers for Disease Control and Prevention. http://
www.cdc.gov/legionella/index.html. Accessed June 26, 2013.
Pedro-Botet ML, et al. Clinical manifestations and diagnosis of legionella infection.http://www.uptodate.
com/home. Accessed June 26, 2013.
Mandell GL, et al. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.
7th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2010.http://www.mdconsult.com/books/
about.do?about=true&eid=4-u1.0-B978-0-443-06839-3..X0001-X--TOP&isbn=978-0-443-06839-
3&uniqId=230100505-57. June 26, 2013.